Stock Analysis
Bruker CorporationBRKR
Sector: Technology · Industry: Laboratory Analytical Instruments
AnalystsBuy21 analystsPrice is 69% of the way from the year's low to its high.
Cash covers 16% of debt · FY 2025.
PMP Verdict
Weak fundamentals
Risks
- Profitability0
- Growth12
Weak fundamentals — valuation is the only support.
Market context
-3.1% today· Z 1.0σ
What's happening with BRKR
Profile
profitability, growth and valuation lag behind.
How is each axis scored?
- Valuation45/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (1.1%)5/25
- P/S (2.4x)20/25
- EV/EBIT (n/a)10/25
- Growth12/100 · Weak
- Revenue CAGR (9.2%)12/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-0.6%)0/25
- ROE (-2.9%)0/25
- Net margin (-2.0%)0/25
- Operating margin (-0.9%)0/25
- Financial Health51/100 · Moderate
- Altman Z (2.63)18/25
- Current ratio (1.73)18/25
- Interest coverage (1.8x)3/25
- Net cash / debt (D/A 25%)12/25
- Quality50/100 · Moderate
- Piotroski F (4/9)10/25
- Beneish M (-2.44)20/25
- FCF conversion (n/a)0/25
- Margin stability (σ 5.2%)20/25
- Moat70/100 · Moderate
- ROIC >12% years (8/10 yrs)20/25
- Median gross margin (47.8%)20/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -0.3%)5/25
Risk Flags
- ⚠Interest coverage 1.8× — thin debt cushion
About Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. Show more
The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Headquarters: BILLERICA, MA · Employees: 11,085 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
45D+P/E (TTM)—
Price / TTM EPS (own statements)
P/FCF37.7xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative · Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
FCF Yield1.1%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -0.2%–2.7% · 29th pct · Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
P/S (TTM)2.39xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.3x–5.7x · 26th pct
EV/EBITDA57.3xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales2.9xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E26.3xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.40xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.79B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.64%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio91.3%D
Grade D: UnsustainableDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Elevated investment: Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
Profitability
0EROIC-0.6%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-2.9%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-1.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-2.0%D
Grade D: LowNet Income / Revenue
Operating Margin-0.9%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin46.4%C
Grade C: AverageGross Profit / Revenue
FCF Margin2.7%D
Grade D: LowFCF / Revenue · Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
True FCF Margin2.1%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost · Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
Growth
12ERevenue CAGR9.2%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-0.4%B
Grade B: FlatShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.6%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
51CAltman Z-Score2.63C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.73xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.88xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage1.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment16.7yD
Grade D: SlowYears to repay net debt via FCF · Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.76xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.16xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
50CPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.44A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income · Elevated investment — CapEx = 51% of operating cash flow, weighing on reported FCF
Margin Stability5.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.8%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.56xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Munch Mark Filed | Munch Mark | Option exercise | -2000 | |
Munch Mark Filed | Munch Mark | SellOpen market sale | -2000 | |
Munch Mark Filed | Munch Mark | Option exercise | +2.0K | |
Pusch Wolfgang Filed | Pusch Wolfgang | SellOpen market sale | -3473 | |
Pusch Wolfgang Filed | Pusch Wolfgang | Grant / award | +2.5K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Pusch Wolfgang Filed | Pusch Wolfgang | Grant / award | +3.1K | |
Bures Thomas Filed | Bures Thomas | Grant / award | +4.0K | |
Srega Juergen Filed | Srega Juergen | Grant / award | +13.7K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
70B+ROIC >12% Years8/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)47.8%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-0.3%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$1.21
Cash & short-term investments per share (Finnhub)
Book Value / Share$15.63
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.87B
Total debt obligations (short + long term)
Cash & Equiv.$298.80M
Cash and short-term investments
Net Debt$1.57B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.46B
Shareholders' equity (book value)
Asset / Liability1.67xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$8.35B
Current Market Capitalization
Beta1.24C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Bruker Corporation (BRKR)
BRKR is down 3.08% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for Bruker Corporation. Altman Z-Score of 2.63 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.44 suggests a low likelihood of earnings manipulation.
- Takes ~16.7 years to repay net debt from free cash flow.
- Interest coverage of 1.8× leaves little room for earnings shocks.
- Bruker Corporation posted a net loss in 1 of 10 available completed fiscal years (2016–2025).
See how BRKR ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for BRKR in the last 30 days.
See BRKR move history →Frequently Asked Questions about BRKR
What is the current Bruker Corporation (BRKR) stock price?
BRKR is trading at $54.80 at the last market close, down 3.08% on the session. PreMarketPrice tracks BRKR pre-market, intraday and after-hours prices.
Is BRKR stock a buy right now?
PreMarketPrice's quantitative model rates Bruker Corporation's financial health at 51/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BRKR stock overvalued?
Bruker Corporation trades at a trailing P/E of n/a and our valuation score rates it 45/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Bruker Corporation report earnings?
No confirmed earnings date is currently scheduled for BRKR. The Earnings section lists recent reports and updates as dates are announced.
What sector does Bruker Corporation operate in?
Bruker Corporation operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does Bruker Corporation do?
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries.
About Bruker Corporation (BRKR) Stock
Bruker Corporation (BRKR) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. As of the latest update, Bruker Corporation is trading at $54.80, down 3.08% on the day with a market capitalization of $8.3 billion. The financial health score for BRKR is 51/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BRKR stock.
BRKR Stock Analysis & Key Metrics
On PreMarketPrice, you can track Bruker Corporation (BRKR) across multiple dimensions:
- Pre-market price & movement: Real-time BRKR stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BRKR with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Bruker Corporation across multiple reporting periods.
- Financial health score: A composite score of 51/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BRKR.
- Sector peers: Compare BRKR against 6 other technology stocks on key financial metrics.
Is BRKR a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Bruker Corporation (BRKR) as an investment. The financial health score of 51/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Bruker Corporation (BRKR) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.